New contender takes on wegovy in major weight loss showdown

NCT ID NCT07150975

Recruiting now Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

Summary

This large, late-stage study aims to see if a new injectable drug called GZR18 works as well or better than the established medication Wegovy (semaglutide) for weight management. It will involve 420 adults who are overweight or have obesity, with or without type 2 diabetes. Participants will be randomly assigned to receive either GZR18 or Wegovy for one year to compare changes in body weight and safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY/OVERWEIGHT IN ADULT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

OBESITY/OVERWEIGHT IN ADULT